Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of HPN-01 in Healthy Subjects
NCT04481594Phase 1Unknown
- Sponsor
- Hepanova, Inc.
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HPN-01 in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Hepanova, Inc. Primary endpoints: Single-dose Pharmacokinetic Parameters, Multiple-dose Pharmacokinetic Parameters and 3 more. Status: unknown.
02
Drugs
HPN-01
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04481594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04481594.